MedTrace Logo

Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis

NCT00847886 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2010-06-03

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate the effect of LX3305 on methotrexate (MTX) pharmacokinetics and to evaluate the safety and tolerability of LX3305 given over 14 days in subjects with stable rheumatoid arthritis that are receiving stable doses of MTX.

Conditions

Interventions

DRUG

LX3305

Daily oral intake of LX3305 for 14 days.

DRUG

LX3305 Placebo

Matching placebo dosing with daily oral intake for 14 days.

DRUG

Methotrexate

Once weekly stable-dose methotrexate.

Sponsors & Collaborators

  • Lexicon Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Philip M. Brown, MD, JD · Lexicon Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00847886 on ClinicalTrials.gov